*Sponsored by Nutriband Inc.
Jeff Ackerman Continues Coverage On Nutriband Inc. (NASDAQ: NTRB) This Morning—Thursday, July 3, 2025
And Here's Why…
Noble Capital Markets Recently Raised Their Target On (NTRB) To $15 Citing Updated FY2027 Eps Projections And Market Positioning.
With Under 4.5M Shares Listed In The Float (NTRB) Could See Significant Swing Potential If Demand Begins To Shift.
Just Two Days Ago (NTRB) Was Added To Several Russell Indexes Increasing Its Visibility Among Institutional Radars.
The Last Two Times We Covered (NTRB) It Moved Approximately 31% And 42% In Short Windows.
Get (NTRB) On Your Screen While It's Still Early…
July 3, 2025 Dear Reader, We're continuing coverage on (NTRB) this morning. Yesterday, (NTRB) reached $10.62 on an approximate 32% move. 
Breaking news from (NTRB) hit the wire this morning. A 25% preferred stock dividend has been approved, with shareholders of record on July 25, 2025 set to receive one preferred share for every four common shares, payable on August 5. Each preferred share will convert to one common share once FDA approval is secured for the company's AVERSA™ Fen-tan-yl product. If left unconverted, preferred shares will be eligible for an annual cash dividend from company profits, as determined by the Board. CEO Gareth Sheridan noted that the company is focused on building shareholder value as it advances toward FDA approval and commercialization of AVERSA Fen-tan-yl, following the recent manufacturing scale-up with Kindeva. If you missed my email from earlier this morning, keep reading to get up to speed. Coming off of our profile from Thursday-Friday of last week, which moved approximately 94% in under 24 hours, we're now turning our attention to Nutriband Inc. (NASDAQ: NTRB) this morning—Wednesday, July 2, 2025. Some stories stay quiet—until they don't. Sometimes, a company that's easy to overlook steps into the spotlight almost overnight. That's exactly what's happening now. (NTRB) is stepping into the spotlight after a string of developments signaling momentum that's hard to ignore. But keep in mind, (NTRB) has a very limited float with less than 4.5 Mln shares listed as available to the public. A few weeks ago, we highlighted (NTRB) as it went from a $6.50 close on Friday, May 30, to $8.55 by Monday, June 2—an approximate 31% move in just days. Before that, we covered it as it went from $5.68 to $8.11 within 24 hours, for an approximate 42% move. Recently, Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, raised his target on (NTRB) to $15, which suggests over 90% upside potential from its recent range. 
Just two days ago, (NTRB) was officially added to several Russell indexes, including growth-focused benchmarks, as part of the 2025 reconstitution. This inclusion could have the potential to draw in the attention of institutional funds and index strategies that track these widely followed benchmarks, expanding market visibility at a pivotal point for the company. On the technical side, Barchart highlighted (NTRB) with 13 out of 13 bullish signals across short-, medium-, and long-term indicators, underscoring the momentum potential in its trend. A New Phase Begins
This is a company with a clear, focused mission: improving the safety of transdermal delivery. Its lead product, AVERSA™ Fen-tan-yl, isn't just another patch—it's designed as an abuse-deterrent transdermal system that could reshape how these therapies are delivered to those who need them while reducing the risks of misuse. In June, (NTRB) and its partner Kindeva announced they had completed the commercial manufacturing process scale-up for AVERSA Fen-tan-yl, marking a pivotal step forward. This move means the company is preparing to file its Investigational (IND) application with the FDA for clinical testing—a necessary gateway to commercial readiness 
Protected By Patents
(NTRB)'s AVERSA™ technology is protected by a broad patent portfolio in 46 countries, including the United States, Europe, Japan, Korea, and China. This coverage strengthens the foundation for its transdermal abuse-deterrent platform, which can be applied to a range of dr-ugs with potential misuse risks, including opi-oids and stimulants. This innovation matters, particularly in a landscape where transdermal fen-tan-yl remains a necessary treatment, yet carries a high risk of misuse. AVERSA aims to address this gap without restricting patient access. A Behind-The-Scenes Moment
Recently, Gareth Sheridan, CEO of Nutriband, emphasized the significance of completing the manufacturing scale-up, calling it "an important step toward the development of a commercially viable product and eventual NDA filing." He underscored how the milestone demonstrates the compatibility of AVERSA technology with established manufacturing processes, providing a clear path toward clinical testing and future commercial rollout. For (NTRB), only a single Phase 1 study is required under the FDA's 505(b)(2) pathway, and the trial is designed specifically to demonstrate that the patch is less preferable for misuse compared to conventional fen-tan-yl patches—an approach considered a low-risk step toward approval. Recent Developments:
- June 3, 2025: The USPTO issued a U.S. patent further expanding coverage for Nutriband's AVERSA technology.
- June 18, 2025: Nutriband and Kindeva completed the commercial manufacturing scale-up for AVERSA Fen-tan-yl, preparing for IND filing and clinical testing.
- The technology holds the potential to become the first abuse-deterrent pain patch on the market, with peak annual U.S. sales estimates ranging from $80M to $200M, according to company statements.
Why (NTRB) Is On Our Radar
This is a pivotal moment for (NTRB). It has moved from a concept to a tangible pathway toward market readiness, backed by a partner with global manufacturing capabilities and a clear regulatory roadmap. The addressable need for safer transdermal therapies remains significant, and the technical and regulatory progress seen over the past weeks positions (NTRB) in a stronger light than many might realize. If you want to follow a company aligned with a clear mission, credible technology, and a tangible timeline for its next steps, (NTRB) deserves a place on your screen right now. Now's the time to keep an eye on (NTRB) as this story continues to unfold. 7 Reasons Why We're Continuing Coverage On (NTRB) This Morning
1. Analyst Raise Target: Noble Capital Markets has raised their target on (NTRB) to $15, citing updated FY2027 EPS projections and market positioning.
2. Limited Float: with under 4.5M shares listed in the float, (NTRB) could witness the potential for significant swings if demand begins to suddenly change. 3. New Index Addition: just two days ago, (NTRB) was added to several Russell indexes, which has the potential to increase its visibility among institutional radars. 4. Recent Momentum: during our last two coverage announcements, (NTRB) has moved approximately 31% and 42% in short windows, reflecting past momentum during key moments. 5. Strong Technical Signals: Barchart recently highlighted (NTRB) with 13 out of 13 bullish signals across short-, medium-, and long-term indicators, underscoring consistent momentum in its trend. 6. Patent-Backed Platform: with coverage in 46 countries, (NTRB) holds broad protection for its AVERSA™ transdermal technology. 7. Milestone Manufacturing Step: in June, (NTRB) and partner Kindeva completed scale-up for AVERSA Fen-tan-yl, preparing for FDA filing. 
Take A Look At (NTRB) While It's Still Early
With a raised $15 target from Noble Capital Markets, a float under 4.5M shares, and fresh inclusion in several Russell indexes just yesterday, (NTRB) could be popping onto more screens. The last two times we covered (NTRB), it moved approximately 31% and 42% in short windows, showing how quickly attention can shift. Now, with Barchart highlighting 13 out of 13 bullish signals, the technical sentiment is hard to ignore. With patent-backed protection in 46 countries and a milestone manufacturing step completed for AVERSA™ Fen-tan-yl, (NTRB) is now preparing for its next phase. We're continuing coverage on (NTRB) this morning. Take a look at this while it's still early. A 25% preferred stock dividend has recently been approved, with shareholders of record on July 25, 2025 set to receive one preferred share for every four common shares, payable on August 5. Keep an eye out for my next update—it could be coming at any moment. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends | 
Tidak ada komentar:
Posting Komentar